The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Investigators working at Gladstone Institutes reported new insights into sleep disturbances and seizures that can be a late consequence of even mild traumatic brain injuries (TBI), and how we may one ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Dianthus Therapeutics Inc. has, appropriately, flowered in springtime. The Waltham, Mass.-based company emerged from stealth with $100 million in series A funding and lofty ambitions to rewrite the ...

Antibodies, also known as immunoglobulins, are specialized proteins produced by the immune system to identify and neutralize foreign invaders, such as viruses, bacteria, and other pathogens. They are ...

Antibodies are disease-fighting proteins that play a crucial role in the immune system. Antibodies recognize infectious invaders, such as bacteria and viruses, and help the body eliminate them.

The second phase of the immune response in that lymphocytes which recognize and bind a foreign antigen undergo initial proliferation to become cloned memory cells and to amplify the protective ...